X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PLETHICO PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PLETHICO PHARMA GLENMARK PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 20.0 -1.1 - View Chart
P/BV x 3.5 0.0 20,887.4% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
PLETHICO PHARMA
Mar-14
GLENMARK PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs930395 235.5%   
Low Rs51731 1,653.0%   
Sales per share (Unadj.) Rs322.6604.4 53.4%  
Earnings per share (Unadj.) Rs28.532.5 87.7%  
Cash flow per share (Unadj.) Rs39.251.3 76.4%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.0473.6 38.6%  
Shares outstanding (eoy) m282.1734.08 828.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.4 636.2%   
Avg P/E ratio x25.46.6 387.2%  
P/CF ratio (eoy) x18.54.2 444.8%  
Price / Book Value ratio x4.00.5 878.8%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2067,262 2,811.8%   
No. of employees `00013.7NA-   
Total wages/salary Rs m18,7181,596 1,172.8%   
Avg. sales/employee Rs Th6,636.8NM-  
Avg. wages/employee Rs Th1,364.7NM-  
Avg. net profit/employee Rs Th586.1NM-  
INCOME DATA
Net Sales Rs m91,03120,598 441.9%  
Other income Rs m914386 236.6%   
Total revenues Rs m91,94520,984 438.2%   
Gross profit Rs m16,1542,818 573.3%  
Depreciation Rs m3,019642 470.0%   
Interest Rs m2,8561,593 179.2%   
Profit before tax Rs m11,193969 1,155.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155-138 -2,279.7%   
Profit after tax Rs m8,0391,107 726.2%  
Gross profit margin %17.713.7 129.7%  
Effective tax rate %28.2-14.3 -197.2%   
Net profit margin %8.85.4 164.3%  
BALANCE SHEET DATA
Current assets Rs m69,88718,877 370.2%   
Current liabilities Rs m32,87911,896 276.4%   
Net working cap to sales %40.733.9 120.0%  
Current ratio x2.11.6 134.0%  
Inventory Days Days8136 226.6%  
Debtors Days Days93198 47.3%  
Net fixed assets Rs m28,8929,861 293.0%   
Share capital Rs m282341 82.8%   
"Free" reserves Rs m51,35312,331 416.5%   
Net worth Rs m51,63516,139 319.9%   
Long term debt Rs m41,4184,706 880.1%   
Total assets Rs m125,95433,146 380.0%  
Interest coverage x4.91.6 306.0%   
Debt to equity ratio x0.80.3 275.1%  
Sales to assets ratio x0.70.6 116.3%   
Return on assets %8.68.1 106.2%  
Return on equity %15.66.9 227.0%  
Return on capital %15.112.3 122.9%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m36,3174,402 824.9%   
Fx outflow Rs m9,7203,184 305.3%   
Net fx Rs m26,5981,219 2,182.8%   
CASH FLOW
From Operations Rs m16,4812,437 676.2%  
From Investments Rs m-10,133-6,265 161.8%  
From Financial Activity Rs m-4,6852,490 -188.1%  
Net Cashflow Rs m1,770-1,337 -132.4%  

Share Holding

Indian Promoters % 48.3 82.7 58.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.3 160.5%  
FIIs % 34.4 5.5 625.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 7.5 140.0%  
Shareholders   56,727 10,665 531.9%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  FDC LTD.  UNICHEM LAB  ORCHID PHARMA LTD  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Dec 14, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS